Anchored in technology exclusively licensed from The Scripps Research Institute, Epic Sciences Inc. is a privately held biotech company developing highly sensitive diagnostic tests to characterize molecularly circulating tumor cells (CTCs) in the blood. The firm is identifying and characterizing rare cells, including circulating tumor cells (CTCs) to provide a better way to detect cancer and the ability to personalize and monitor cancer treatments. The Epic team has developed a powerful rare-cell detection and characterization platform and is working on clinically proven predictive tests to detect and monitor cancer at the individual cell level. With a proprietary rare-cell detection engine, Epic can provide insights to clinical, biotech, pharmaceutical and academic teams on how cancer emerges, mutates and remits so they can make pivotal decisions at every point in patient treatment with greater certainty. Recognizing the unique nature of each persons cancer, Epic can offer truly personalized diagnostic tests, while being non-invasive for the patient. The firm has developed the first clinically proven predictive test for metastatic castration-resistant prostrate cancer (mCRPC), the Epic AR-V7 test. Using the same rare-cell detection platform and Epics biobank of over 30,000 blood samples, each profiled with predictive biomarkers, the firm is partnering with leading pharmaceutical and biotechnology companies, major cancer centers, the National Cancer Institute (NCI), and the National Institutes of Health (NIH) to pursue additional predictive tests for breast, ovarian, colon and other cancers and diseases with the objective of providing cancer care and therapies that are as precise, safe and life-sustaining as possib
